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Collagen-hydroxyapatite scaffolds are outstanding materials for bone tissue engineer-
ing as they are biocompatible, bioresorbable, osteoconductive, and osteoinductive.
The objective of the present work was to assess the potential of increasing their
regenerative capacity by functionalising the scaffolds for therapeutic delivery. This
was achieved by the utilization of polymeric drug carriers. With this purpose,
alginate, chitosan, gelatine, and poly(lactic-co-glycolic acid) (PLGA) microparticles
eluting PTHrP 107-111, an osteogenic pentapeptide, were fabricated and tested by
incorporating them into the scaffolds. Among them, PLGA microparticles show
the most promising characteristics for use as drug delivery devices. Following the
incorporation of the microparticles, the scaffolds maintained their interconnected
porous structure and the mechanical properties of the materials were not adversely
affected. In addition, the microparticles released all their PTHrP 107-111 cargo. Most
importantly, the delivered peptide proved to be bioactive and promoted enhanced
osteogenesis as assessed by alkaline phosphatase production and osteocalcin and
osteopontin gene expression when pre-osteoblastic cells were seeded on the scaffolds.
While the focus was on bone repair, the release system described in this study can
be used for the delivery of therapeutics for healing and regeneration of a variety of
tissue types depending on the type of collagen scaffold chosen. C 2014 Author(s). All
article content, except where otherwise noted, is licensed under a Creative Commons
Attribution 3.0 Unported License. [http://dx.doi.org/10.1063/1.4902833]
The role of scaffolds for bone tissue engineering has evolved from being a supportive matrix for
cell proliferation and differentiation to also acting as a reservoir for the controlled release of active
molecules that enhance tissue regeneration.1 In this sense, significant efforts have been made with
ceramics, synthetic polymers, and hydrogels for developing complex devices for the sequential and
responsive release of growth factors and other therapeutics.2–4 We have recently developed, in our
labs, three dimensional porous collagen-hydroxyapatite (CHA) scaffolds with immense potential
for bone repair as they are biodegradable, biocompatible, osteoconductive, and osteoinductive.5,6
However, enhancing their regenerative capacity through the incorporation and release of therapeu-
tics presents challenges given the chemically labile nature of proteins. Consequently, the utilization
of many post-fabrication procedures for functionalising matrices to achieve controlled drug-delivery
may compromise the integrity of the scaffold.
One way to incorporate drugs into the CHA scaffold would be to load the therapeutics into poly-
meric carriers that could be subsequently integrated into the protein network during its fabrication,
aAuthor to whom correspondence should be addressed. Electronic mail: fjobrien@rcsi.ie
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TABLE I. Fabrication conditions for the PTHrP 107-111 loaded polymeric microparticles by
spray-drying using a Buchi mini spray dryer B-290.
Polymer
(1 g)
Solvent
(200 ml water)
Inlet temperature
(◦C)
Aspiration
(%)
Pump
(%)
Nozzle
cleaning
Alginate Water 140 80 15 4
Chitosan 1% acetic acid
1.6% glutaraldehyde
160 80 15 6
Gelatine 0.1% mannitol 160 80 15 4
an approach that has been successfully used in other collagen-based materials.7,8 These carriers
would ensure the stability of the drugs during the fabrication process and would also allow their
release after implantation. In addition, they would act as a reservoir, protecting the therapeutic
molecules from degradation in vivo. With this in mind, the present work evaluated the feasibility
of incorporating four different polymeric microparticles into CHA scaffolds and determined the ef-
fects on the scaffold’s characteristics. Alginate, chitosan, gelatine, and poly(lactic-co-glycolic acid)
(PLGA) were chosen for the fabrication of the microparticles, as these biocompatible polymers have
been widely used with drug delivery purposes.9–12 As a proof of concept, prior to incorporation
into the scaffolds, the microparticles were loaded with the fragment 107-111 from the parathyroid
hormone (PTHrP 107-111), a pentapeptide with pro-osteogenic activity.13 The release of the peptide
from the microparticles/scaffold composites was analysed, and the anabolic effect of the released
PTHrP 107-111 on pre-osteoblastic cells was tested in vitro.
Alginate, chitosan, gelatine, and PLGA were chosen as polymers for the encapsulation of the
model molecule, the pro-osteogenic peptide PTHrP 107-111.
A spray drying process, detailed elsewhere,14 was used for the fabrication of alginate, gelatine,
and chitosan microparticles. Briefly, in this fabrication procedure, a polymeric feed solution is
atomized and forced to pass through a chamber at high temperature where the solvent from the
droplets is evaporated. As a result, particulate powder of the polymer is collected. Drug loaded
materials can be produced by this method by adding the therapeutic molecule, PTHrP 107-111 in
the present work, to the polymeric solution.
Table I summarizes the conditions used for the fabrication of the different microparticles
with a Buchi Mini Spray Dryer B-290. In all cases, the ratio of PTHrP 107-111:polymer was
25.2 mg:100 g. Alginate microparticles were crosslinked after fabrication; with this purpose, the
microparticles were suspended in 10 ml acetonitrile and then poured into 1.2% (w/v) calcium
chloride while stirring for 10 min. Afterwards, they were vacuum filtered through a 0.45 µm nylon
membrane, washed twice with 10 ml distilled water, and freeze-dried at −56 ◦C overnight.
PLGA microparticles were fabricated by a water-in-oil-in-water emulsion (W/O/W) method.
Briefly, 0.5 ml of an aqueous solution of 9.45 mg of PTHrP 107-111 was added to 5 ml of
dichloromethane where 375 mg of PLGA had been previously solved. A primary emulsion was
generated by ultrasonication of this mixture. This W/O emulsion was added dropwise while soni-
cating to 30 ml of an aqueous solution containing 1 g of polyvinyl alcohol (PVA) and 1.13 g of
NaCl. The resulting W/O/W emulsion was dispersed into 70 ml of the same aqueous solution. This
emulsion was stirred for 4 h at room temperature and the resulting microparticles were collected by
centrifugation (5000 rpm, 10 min). The particles were washed three times with 1.13% (w/v) NaCl
and freeze-dried at −56 ◦C overnight.
Morphological characterization was carried out by Scanning Electron Microscopy (SEM) using
a Zeiss Supra Variable Pressure Field Emission Scanning Electron Microscope. For SEM observa-
tions, samples were mounted on copper studs with carbon glue and then sputtered with gold.
In order to assess the release kinetics of PTHrP 107-111 from the microparticles, 20 mg of each
composition were immersed in 2 ml phosphate buffered saline (PBS) at 37 ◦C. At given timepoints,
the medium was removed after centrifugation and replaced by fresh pre-warmed PBS. Media were
analysed by high performance liquid chromatography (HPLC) following a protocol detailed by
Manzano et al.15
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The fabrication of the CHA scaffolds was done following a procedure previously published
and patented by our group.16 Briefly, 1.8 g of micro-fibrillar bovine tendon collagen was added
to 320 ml of 0.5 M acetic acid solution. This was blended at 15 000 rpm for 90 min using an
overhead blender in a reaction vessel which was kept at 4 ◦C using a circulation system to prevent
denaturation of the collagen due to the heat generated during the process. Aliquots of 10 ml of a
solution of 3.6 g of hydroxyapatite particles, with a mean diameter of 5 µm (Plasma Biotal Limited,
North Derbyshire, UK), in 40 ml of 0.5 M acetic acid solution were added every 60 min, and the
resulting slurry was blended for 60 additional minutes. Then, the slurry was degassed by vacuum
in order to remove air bubbles that could produce uncontrolled porosity in the final scaffold. A
suspension of 100 mg of the microparticles (fabricated using the techniques described above) in
1 ml distilled water was gently mixed with 9 ml of this CHA slurry, and the mixture was pipetted
into a stainless steel tray prior to lyophilization at −10 ◦C using a constant cooling freeze-drying
protocol. Depending on the microparticle type, scaffolds are denoted PLGA-CHA, alginate-CHA,
chitosan-CHA, and gelatine-CHA. A similar procedure was carried out adding 1 ml of distilled
water to the slurry in order to produce a CHA scaffold, used as blank control, which was denoted
blank-CHA. After freeze-drying, both sides of the scaffolds were exposed to short wavelength
(254 nm λ) UV-light (at 2300 µW/cm2) for 15 min in order to crosslink them.17
The porosity of the scaffolds with and without microparticles was calculated by the following
equation:
% porosity = 100 × [1 − (ρ actual/ρ theoretical)] .
The actual density (ρ actual) of the scaffolds was calculated by dividing the actual mass of the
scaffolds to calculated volume of the scaffolds. The theoretical density (ρ theoretical) was estimated
using the values of collagen, PLGA, chitosan, gelatine, and/or alginate taken from the literature.
In order to check the influence of the addition of microparticles into the scaffold over its
mechanical properties, wet compression testing was performed using a uniaxial tensile testing ma-
chine (Z050, Zwick/Roell, Ulm, Germany). Disks of scaffolds (n = 9) with a diameter of 6.5 mm
were pre-hydrated prior to transfer to the testing rig which contained distilled water. Uniaxial
compression testing was performed up to a maximum strain of 10%. The modulus was calculated
from the slope of the stress-strain curve over the range of 2%–5% strain. Compressive testing results
were analysed using an in-house designed Microsoft Excel macro.
SEM characterization of the surface and the cross-section of the different composite scaffolds
were performed using Zeiss Supra Variable Pressure Field Emission Scanning Electron Microscope.
Samples were mounted on copper studs and were sputtered with gold prior to observation.
In order to assess the PTHrP 107-111 release kinetics from the composite scaffolds, 6.5 mm
diameter disks were soaked in 2 ml PBS at 37 ◦C. At given timepoints, the medium was replaced
with fresh pre-warmed PBS and analysed by HPLC.
MC3T3-E1 murine pre-osteoblasts were used to study the effects of the peptide on osteoblast
differentiation in vitro since they exhibit similar properties as osteoprogenitor cell lines including
high alkaline phosphatase (ALP) activity.18 These cultures form calcified bone tissue in a process
closely resembling intramembranous ossification.19 MC3T3-E1 cells were cultured in α-MEM sup-
plemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 2% penicillin/streptomycin.
Media were changed every 3 days and cells were removed from the flasks using a trypsin–EDTA
(ethylenediaminetetraacetic acid) solution 0.25%. Cells (3 × 105, quantified with an haemocytome-
ter) were seeded on the surface of 6.5 mm diameter CHA scaffolds and CHA-PLGA scaffolds
(1.5 × 105 cells on each side) and then incubated in 2 ml of pro-osteogenic medium (α-MEM
supplemented with 10% FBS, 50 µg/ml ascorbic acid, 10 mM β-glycerol-phosphate, 1% peni-
cillin/streptomycin, and 0.25 mg/ml amphotericin B) under standard conditions (37 ◦C, 5% CO2).
The osteogenic potential of MC3T3-E1 cells on the scaffolds was assessed and compared to
blank CHA scaffolds by quantifying the activity of ALP, a widely exploited early biochemical
marker for osteogenic activity 3 and 7 days post-seeding.20 At the endpoint of the study, constructs
containing MC3T3-E1 cells were washed in PBS, lysed according to the manufacturer’s protocol
in lysis buffer (SensoLyte pNPP Alkaline Phosphatase Assay Kit), and incubated at 4 ◦C. The
supernatant was collected for quantification of ALP. This method utilizes p-nitrophenylphosphate
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(pNPP) that is hydrolyzed by ALP to produce a yellow product. The amount of colored product is
proportional to the amount of enzyme in the reaction mixture.
In order to determine the expression of different osteogenic genes as indicators of differenti-
ation into an osteoblastic phenotype, ribonucleic acid (RNA) was extracted from MC3T3-E1 cells
after 14 days of culture by using Qiazol Lysis Reagent (Qiagen) and RNeasy Mini Kit (Qiagen).
RNA was quantified using a Nanodrop 2000 Micro-Volume UV–Vis Spectrophotometer for nucleic
acid and protein quantitation (Thermo Scientific). RNA extraction was followed by complementary
DNA reverse transcription by using QuantiTect Reverse Transcription Kit (Qiagen). The samples
were prepared for polymerase chain reaction (PCR) analysis by using SYBR Green PCR kit (Qia-
gen). Real time polymerase chain reaction (RT–PCR) was performed on 10 ng RNA, and reactions
were run on a Real–Time PCR System (Eppendorf Mastercycler ep Realplex 4S_Version1). Gene
expression of osteopontin (OPN, Qiagen, QT00157724), osteocalcin (OCN, Qiagen, QT00259406),
and 18S (Qiagen, QT01036875) as an endogenous control were investigated. Results were analyzed
by using 2-∆∆ CT Method.21 Fold change is defined as the relative expression compared to the
expression of each gene from cells seeded on blank CHA scaffolds and cultured at 37 ◦C.
The data are represented as means ± standard error of the mean. Statistics were carried out
using GraphPad Prism software using a general linear model ANOVA with Bonferroni posttest
analysis performed for multiple comparisons. All experiments were performed with a sample size of
3 per treatment group unless otherwise stated. Statistical significance was taken at p < 0.05 unless
otherwise stated.
SEM observations, shown in Figure 1, confirm that irrespective of the fabrication procedure
and the composition, all microparticles were in the 1–10 µm size range, in concordance with results
obtained by dynamic light scattering measurements (data not shown). The micrographs also demon-
strate that PLGA, chitosan, and alginate microparticles had a spherical shape with a smooth surface,
while gelatine based materials had a wrinkled texture, a phenomenon that has been described before
for this type of products.22
As shown in Figure 2, diverse peptide release profiles were obtained from the different micro-
particles in the in vitro studies. On the one hand, PLGA and alginate particles released all their
contents in the first 10 h of the study while, on the other hand, the delivery from chitosan and
gelatine microparticles was sustained until 48 h. There was no further release of peptide from that
timepoint to the end of the study (14 days) in any of the studied polymers (data not shown).
Having determined that polymeric microparticles effectively eluted PTHrP 107-111 with the
experimental procedures detailed above, they were then incorporated into the CHA slurry, prior
to its lyophilisation. SEM micrographs of the final constructs, displayed in Figure 3, demonstrate
FIG. 1. SEM micrograph of alginate (a), chitosan (b), PLGA (c), and gelatine (d) PTHrP 107-111 loaded microparticles.
Scale bar represents 10 µm. In contrast with the rest of polymers, gelatine microparticles have a wrinkled texture.
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FIG. 2. PTHrP 107-111 release kinetics from the different polymeric microparticles. The percentage of drug released is
calculated from the amount of peptide added during the fabrication of the microparticles. PLGA and alginate release the
peptide content in the first 10 h of the study, while gelatine and chitosan display a sustained delivery.
FIG. 3. SEM micrographs of collagen-hydroxyapatite scaffolds incorporating the different polymeric microparticles. Images
from top to bottom were taken at 6000, 1000, and 100× magnification, respectively. Scale bar from top to bottom represents
10, 50, and 500 µm, respectively. With the exception of gelatine, microparticles can be distinguished in the walls of the
microparticle/collagen scaffolds.
that the microparticles were homogeneously distributed through the CHA scaffolds walls, with the
exception of gelatine microparticles which could not be distinguished in the sample. In addition, the
micrographs suggest that the porosity and pore interconnectivity were maintained in all scaffolds
following microparticle incorporation. These observations are corroborated by the results from
porosity quantification (Figure 4(a)), as all the scaffolds had porosity values over 96%.
The incorporation of the microparticles into the collagen network did not have a negative effect
on the mechanical properties of the CHA scaffolds, as shown in Figure 4(b). Indeed, the compres-
sive modulus of chitosan-CHA scaffold was significantly higher than the blank-CHA control.
When the PTHrP 107-111 release profiles were analysed, gelatine-CHA degraded in the PBS
before the first sample was obtained (2 h) and no PTHrP 107-111 was detected in the media where
the chitosan-CHA scaffolds were releasing, at any of the timepoints. Thus, only the release of
PTHrP 107-111 from alginate-CHA and PLGA-CHA scaffolds, displayed in Figure 5, could be
studied. The percentage of drug release shown in Figure 5 has been calculated based on the data
presented in Figure 2, by assuming that the release from the microparticles after 14 days represents
the total drug incorporated into these microparticles. The drug delivery profiles from these scaffolds
are similar to those determined from the corresponding microparticles alone, with the majority of
 This article is copyrighted as indicated in the article. Reuse of AIP content is subject to the terms at: http://aplmaterials.aip.org/about/rights_and_permissions
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FIG. 4. (a) Porosity and (b) mechanical properties of collagen-hydroxyapatite scaffolds incorporating alginate, chitosan,
gelatine, or PLGA microparticles. ∗∗∗p < 0.001 denotes significance compared with all other groups.
FIG. 5. Release profiles of PTHrP 107-111 from PLGA and alginate microparticles incorporated into collagen-
hydroxyapatite scaffolds. The percentage of the drug released is calculated from the total amount of peptide incorporated
with the microparticles.
the drug being released during the first 10 h. Interestingly, only around 60% of the incorporated
drug was delivered from the alginate-CHA samples after 14 days of study (data not shown).
Taking these results into consideration, the PLGA-CHA scaffolds, which displayed the best
properties in terms of peptide delivery efficiency, were selected for further in vitro studies where
bioactivity assays were performed with preosteblastic cells, results of which are detailed in the
following section.
The osteogenic differentiation potential of MC3T3-E1 cells in direct contact with a peptide
eluting PLGA-CHA scaffold and a blank-CHA scaffold was assessed and compared. ALP cellular
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FIG. 6. (a) MC3T3 ALP activity following 3 and 7 days culture on PTHrP 107-111 eluting and blank collagen hydroxyapatite
scaffolds. ∗p < 0.001 denotes significance compared with the blank collagen hydroxyapatite scaffolds. (b) Osteocalcin
and osteopontin relative expression of MC3T3 after 14 days of culture on PTHrP 107-111 eluting and blank collagen
hydroxyapatite scaffolds. ∗p < 0.001 and ∗∗p < 0.01 denote significance compared with the blank CHA scaffolds.
activity, an early marker for osteoblastic differentiation, was examined after culturing the cells on
the scaffolds for 3 and 7 days (Figure 6(a)). A significant increase in ALP activity was observed
from cells grown on peptide eluting scaffolds compared to cells grown on blank CHA controls at 3
days.
Figure 6(b) shows the osteogenic gene expression results from cells cultured on the scaffolds
for 14 days. These results corroborate the pro-osteogenic effect implied by ALP analysis, as ev-
idenced by significant increases in expression of the osteogenic markers OCN and OPN in cells
cultured on peptide eluting PLGA-CHA scaffolds.
The aim of the present study was to assess the feasibility of incorporating different therapeutic-
loaded polymeric microparticles into a CHA scaffold and assess their potential to enhance osteoge-
nesis. This experimental approach may overcome the inherent difficulties of loading drugs in these
bioactive materials, as they are fabricated using acidic solvents which can harm labile products such
as proteins or peptides. With this purpose in mind, the microparticles were mixed with the CHA
slurry during an intermediate fabrication step, prior to the final freeze-drying process. In order to
determine if a bioactive molecule could be loaded and released from these microparticle-scaffold
constructs, the pro-osteogenic pentapeptide PTHrP 107-111 was preloaded into the microparticles.
This work demonstrates that, from the evaluated polymers, CHA scaffolds incorporating PLGA
microparticles show the most promising characteristics for use as drug delivery devices. Follow-
ing the incorporation of the PLGA microparticles, the scaffold retained its interconnected porous
structure and the mechanical properties of the materials were not adversely affected. In addition, the
microparticles released all their PTHrP 107-111 cargo from the scaffolds unlike the other compo-
sitions. Most importantly, the delivered peptide proved to be bioactive and promoted enhanced
osteogenesis as assessed by alkaline phosphatase production and osteocalcin and osteopontin gene
expression when pre-osteoblastic cells were seeded on the scaffolds.
The fabrication of the PTHrP 107-111 loaded microparticles was carried out by a double
emulsion technique (with PLGA) and a spray-drying process (with alginate, chitosan, and gelatine)
which yielded materials with the expected micrometric size and spherical shape.9–12 Regarding
the PTHrP 107-111 delivery, PLGA and alginate microparticles released their cargo after only
10 h of immersion in PBS, while gelatine and chitosan delivered the peptide in a more controlled
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fashion, which suggests a stronger chemical interaction between the pentapeptide and these specific
polymers.
The incorporation of PLGA, alginate, and chitosan microparticles to the CHA slurry and its
subsequent freeze-drying yielded composite scaffolds with microparticles homogeneously distrib-
uted throughout the scaffold walls. However, gelatine microparticles were not distinguishable under
SEM examination, which may indicate that the gelatine dissolved as a result of the acidic pH of the
slurry. In addition, gelatine-CHA scaffolds degraded very quickly in PBS during the drug release
studies confirming that these microparticles are not suitable for inclusion into the collagen matrix
using the procedure described in this study. Encouragingly, the addition of the microparticles did
not have a negative effect on the mechanical properties of the CHA scaffolds. Indeed, the incorpo-
ration of chitosan augmented significantly the compressive modulus of the scaffolds. The increased
stiffness, which may be beneficial for osteoblasts attachment, differentiation, and proliferation, may
be attributed to the presence of residual glutaraldehyde, which was used for crosslinking the micro-
particles.23 Glutaraldehyde is a well-known crosslinking agent of protein-based scaffolds, and its
existence in the CHA slurry would also explain that the PTHrP 107-111 was not released from
the chitosan-CHA scaffolds, as the peptide was probably also being crosslinked to the collagen
matrix.24 Importantly, the cytotoxicity of glutaraldehyde has been well documented and thus the
existence of its residues in the scaffold should be minimized.25
PTHrP 107-111 release was detected from alginate-CHA and PLGA-CHA composites only.
The delivery kinetics from these scaffolds in vitro followed the same trend as the release from the
corresponding microparticles alone, i.e., quick release in 10 h. However, while PLGA microparti-
cles released all their cargo from the scaffolds, assuming that the release from the microparticles
after 14 days represents the total drug incorporated into these microparticles, only a fraction of
around 60% was delivered from alginate-CHA samples. This is probably due to the degradation of
the peptide accumulated in the outer layers of the microparticles when they were immersed in the
acidic CHA slurry before lyophilisation; the aggregation of encapsulated molecules on the surface
of spray-dried microparticles is an expected consequence of this fabrication process.26 Thus, PLGA
microparticles-CHA scaffolds were selected for carrying out in vitro studies in order to check the
bioactivity of the released PTHrP 107-111.
The analysis of the effect of the peptide on osteoblasts grown in direct contact with the
PLGA-CHA scaffolds confirmed its pro-anabolic activity as the released PTHrP 107-111 led to a
significant increase in ALP activity, which is indicative of an enhancement of cell differentiation
towards a pro-osteogenic lineage. Further confirmation of the anabolic effect of released peptide
was obtained from the augmented expression of OPN and OCN genes, markers of distinct stages
of osteoblast maturation. The significant increase in the levels of these two genes in cells grown on
PLGA-CHA scaffolds is indicative of differentiation and mineralization, corroborating the previous
ALP results. This pro-osteogenic effect can be attributed to the release of the peptide from the
scaffolds,27 as it was not observed in a parallel study carried out with non-eluting PLGA-CHA
constructs (data not shown). Thus, in vitro results confirm that PTHrP 107-111 was bioactive after
loading into the microparticles and the subsequent incorporation into the CHA scaffold.
Taken together, these results demonstrate the development of a fabrication procedure which
allows microparticles to be incorporated in CHA scaffolds for the local delivery of therapeutics. The
present study shows that, for releasing a small molecule such as PTHrP 107-111, PLGA-CHA is
the optimal combination. However, promising results were also obtained for alginate-CHA, demon-
strating their potential for the targeted release of drugs. Chitosan-CHA scaffolds could also be used
if a non-toxic alternative crosslinking method was employed during the fabrication of the micropar-
ticles. The slow release from these microparticles, which may have been affected by glutaraldehyde,
could be attractive for the delivery of certain therapeutics and may be tuned depending on the
cross-linking agent utilised. It must be noted that, in order to avoid the potential toxicity of a high,
burst release, the release kinetics from these constructs can be tuned by modifying and function-
alizing the microparticles prior to their incorporation into the CHA scaffold, an approach that is
being studied currently in our laboratories. Also, by varying the composition of the collagen-based
scaffold, this strategy can be applied to deliver therapeutics to a wide range of target tissues.
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The fabrication of collagen-hydroxyapatite scaffolds incorporating polymeric microparticles
for the localized delivery of therapeutics was investigated. The pentapeptide PTHrP 107-111 was
tested as model molecule for the delivery studies. Scaffolds incorporating PLGA microparticles
displayed porosity and mechanical properties similar to those of collagen-hydroxyapatite scaffolds
along with the highest ratios of peptide loading and release. In addition, PTHrP 107-111 released
from these composite scaffolds showed pro-osteogenic effects on bone cells, demonstrating the
potential of these systems for bone tissue regeneration. However, by tuning the release kinetics, the
active molecule, and the composition of the collagen scaffold, these platforms have the potential to
be applied for a wide range of applications in addition to bone.
This publication has emanated from research conducted with the financial support of Sci-
ence Foundation Ireland under Grant No. SFI 12/TIDA/B2383. E.Q. and F.J.O. acknowledge
European Research Council for funding (239685-CollRegen-ERC-2009-STG). N.C. acknowledges
CEMACUBE (Erasmus Mundus, Action 1, Common European Master’s course in Biomedical
Engineering) for her scholarship.
1 S. H. Lee and H. Shin, Adv. Drug Delivery Rev. 59(4–5), 339–359 (2007).
2 V. Aina, C. Magistris, G. Cerrato, G. Martra, G. Viscardi, G. Lusvardi, G. Malavasi, and L. Menabue, Langmuir 30(16),
4703–4715 (2014).
3 A. A. Amini and L. S. Nair, Biomed. Mater. 7(2), 024105 (2012).
4 K. Lee, E. A. Silva, D. J. Mooney, and J. R. Soc, Interface 8(55), 153–170 (2011).
5 J. P. Gleeson, N. A. Plunkett, and F. J. O’Brien, Eur. Cells Mater. 20, 218–230 (2010).
6 F. G. Lyons, J. P. Gleeson, S. Partap, K. Coghlan, and F. J. O’Brien, Clin. Orthop. Relat. Res 472(4), 1318–1328 (2014).
7 Z. S. Patel, M. Yamamoto, H. Ueda, Y. Tabata, and A. G. Mikos, Acta Biomater. 4(5), 1126–1138 (2008).
8 M. Biondi, L. Indolfi, F. Ungaro, F. Quaglia, M. I. La Rotonda, and P. A. Netti, J. Mater. Sci.: Mater. Med. 20(10), 2117–2128
(2009).
9 R. A. Jain, Biomaterials 21(23), 2475–2490 (2000).
10 L. Solorio, C. Zwolinski, A. W. Lund, M. J. Farrell, and J. P. Stegemann, J. Tissue Eng. Regener. Med. 4(7), 514–523 (2010).
11 S. A. Agnihotri, N. N. Mallikarjuna, and T. M. Aminabhavi, J. Controlled Release 100(1), 5–28 (2004).
12 S. Takka and F. Acarturk, J. Microencapsulation 16(3), 275–290 (1999).
13 D. Lozano, M. Manzano, J. C. Doadrio, A. J. Salinas, M. Vallet-Regi, E. Gomez-Barrena, and P. Esbrit, Acta Biomater. 6(3),
797–803 (2010).
14 N. Sivadas, D. O’Rourke, A. Tobin, V. Buckley, Z. Ramtoola, J. G. Kelly, A. J. Hickey, and S. A. Cryan, Int. J. Pharm.
358(1–2), 159–167 (2008).
15 M. Manzano, D. Lozano, D. Arcos, S. Portal-Nunez, C. L. la Orden, P. Esbrit, and M. Vallet-Regi, Acta Biomater. 7(10),
3555–3562 (2011).
16 F. J. O’Brien, J. Gleeson, and N. Plunkett, “A collagen/hydroxyapatite composite scaffold, and process for the production
thereof,” patent number WO 2008096334 A3 (14 August 2008).
17 K. S. Weadock, E. J. Miller, E. L. Keuffel, and M. G. Dunn, J. Biomed. Mater. Res. 32(2), 221–226 (1996).
18 V. Kartsogiannis and K. W. Ng, Mol. Cell. Endocrinol. 228(1–2), 79–102 (2004).
19 H. Sudo, H. A. Kodama, Y. Amagai, S. Yamamoto, and S. Kasai, J. Cell Biol. 96(1), 191–198 (1983).
20 A. Yamaguchi, T. Komori, and T. Suda, Endocr. Rev. 21(4), 393–411 (2000).
21 K. J. Livak and T. D. Schmittgen, Methods 25(4), 402–408 (2001).
22 M. L. Bruschi, M. L. C. Cardoso, M. B. Lucchesi, and M. P. D. Gremiao, Int. J. Pharm. 264(1–2), 45–55 (2003).
23 M. G. Haugh, C. M. Murphy, R. C. McKiernan, C. Altenbuchner, and F. J. O’Brien, Tissue Eng., Part A 17(9–10), 1201–1208
(2011).
24 H. W. Kang, Y. Tabata, and Y. Ikada, Biomaterials 20(14), 1339–1344 (1999).
25 A. Bigi, G. Cojazzi, S. Panzavolta, K. Rubini, and N. Roveri, Biomaterials 22(8), 763–768 (2001).
26 R. Vehring, Pharm. Res. 25(5), 999–1022 (2008).
27 A. Lopez-Noriega, E. Ruiz-Hernandez, E. Quinlan, G. Storm, W. E. Hennink, and F. J. O’Brien, J. Controlled Release 187,
158–166 (2014).
 This article is copyrighted as indicated in the article. Reuse of AIP content is subject to the terms at: http://aplmaterials.aip.org/about/rights_and_permissions
Downloaded to IP:  193.1.229.2 On: Tue, 09 Jun 2015 13:58:24
